Announced Fri, 14 Aug · 20:46 IST
Nectar Lifesciences Q1 FY27 results: net loss of Rs 13.14 cr, board changes
NECLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-2.7%1-day move
₹11.10
prior close
₹11.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+4.5+4.5+4.5+3.4-2.7-4.8-7.2-4.5-2.7+12.3+9.3-0.9——
Up moveDown movePending
AI summary
Nectar Lifesciences posted a standalone net loss of Rs 13.14 cr for Q1 FY27 (ended Jun 30, 2026) versus Rs 63.23 cr loss in Q1 FY26. Total income rose to Rs 6.29 cr from Rs 0.31 cr. A Rs 25.13 cr loss from market-linked mutual fund, ETF and equity investments hit P&L. The firm has sold its capsule business via slump sale and is pivoting to real estate. Board appointed Dr Gunmala Suri as director and set 31st AGM for Sept 18, 2026. Going concern basis used given liquidity and solvency.
Likely market impact
Continued losses and pivot to a new business raise uncertainty; share price may stay under pressure near term.